Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition-Reference-Cited by-同舟云学术

Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition

Published:2019-06 Issue:6 Volume:27 Page:1139-1152
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Jennings Victoria A.,Scott Gina B.,Rose Ailsa M.S.,Scott Karen J.,Migneco Gemma,Keller Brian,Reilly Katrina,Donnelly Oliver,Peach Howard,Dewar Donald,Harrington Kevin J.,Pandha Hardev,Samson Adel,Vile Richard G.,Melcher Alan A.,Errington-Mais Fiona

Funder

National Institute for Health Research

Cancer Research UK

Yorkshire Cancer Research

Kay Kendall Leukaemia Fund

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference57 articles.

1. Review: Oncolytic virotherapy, updates and future directions;Fountzilas;Oncotarget,2017

2. Herpes simplex virus oncolytic vaccine therapy in melanoma;Sivendran;Expert Opin. Biol. Ther.,2010

3. Recent Clinical Experience With Oncolytic Viruses;Donnelly;Curr. Pharm. Biotechnol.,2012

4. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy;Ribas;Cell,2017

5. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor;Hu;Clin. Cancer Res.,2006

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling;Journal for ImmunoTherapy of Cancer;2024-07

2. Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signalling;2024-04-03

3. Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma;Expert Review of Clinical Immunology;2024-03-27

4. Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy;Molecular Therapy: Oncology;2024-03

5. Molecular insights and promise of oncolytic virus based immunotherapy;Advances in Protein Chemistry and Structural Biology;2024